Abstract:PURPOSE: To sensitize non-small cell lung cancer (NSCLC) to radiotherapy by tumor-specific delivery of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene.EXPERIMENTAL DESIGN: The TRAIL was delivered to human NSCLC cell lines and normal human bronchial epithelial cells by the replication-defective adenoviral vector Ad/TRAIL-F/RGD using a tumor-specific human telomerase reverse transcriptase promoter. Cancer growth was studied using 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide inner salt and clonogenic assays. Activation of the apoptosis pathway was analyzed in a Western blot and sub-G(1) DNA accumulation. A xenograft mouse lung cancer model was treated by intratumoral injections of Ad/TRAIL-F/RGD and local radiotherapy; the other groups received one of these treatments alone or a control agent. Apoptosis and TRAIL expression in tumors were also analyzed.RESULTS: Ad/TRAIL-F/RGD specifically targets human NSCLC cells without significant effect in normal human bronchial epithelial cells. The combination of Ad/TRAIL-F/RGD and radiotherapy significantly improved cell-killing effect in all NSCLC cell lines tested (P < 0.05). Expression of TRAIL showed a dose-dependent relationship with Ad/TRAIL-F/RGD, and radiation seemed to increase TRAIL expression. Activation of the apoptosis by TRAIL and radiation was shown by activation of caspase-9, caspase-8, caspase-3, and poly(ADP-ribose) polymerase and increased DNA sub-G(1) accumulation. The combination of TRAIL and radiotherapy significantly increased apoptosis in vivo, inhibited tumor growth, and prolonged mean survival in mice bearing human NSCLC to 43.7 days compared with 23.7 days (TRAIL only) and 16.5 days (radiotherapy only; P < 0.05).CONCLUSIONS: The combination of Ad/TRAIL-F/RGD and radiotherapy significantly improved therapeutic efficacy in suppressing NSCLC tumor growth and prolonging survival. Ad/TRAIL-F/RGD may improve the therapeutic ratio of radiotherapy in NSCLC.

Suppression of Teratocarcinoma Growth by Soluble Trail Gene Expression Driven by the Progression-Elevated Gene-3 Promoter

Long-term tumor-free survival from treatment with the GFP–TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells

Targeted Expression of Green Fluorescent Protein/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Fusion Protein from Human Telomerase Reverse Transcriptase Promoter Elicits Antitumor Activity Without Toxic Effects on Primary Human Hepatocytes

Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms.

Tumor necrosis factor-related apoptosis-inducing ligand gene on human colorectal cancer cell line HT29.

Anti-liver Cancer Activity of TNF-related Apoptosis-Inducing Ligand Gene and Its Bystander Effects.

Treatment of patient tumor-derived colon cancer xenografts by a TRAIL gene-armed oncolytic adenovirus

[Activity of the TNF-related Apoptosis-Inducing Ligand Gene Expressed from the Htert Promoter on Colon Cancer Cell Line HT-29].

Construction of eukaryotic recombinant sTRAIL expression vector and Its effect on C6 glioma xenograft in athymic mice

Lentivirus-mediated Gene Transfer of Human Strail Induced Apoptosis in SGC-7901 Cells

[Action of Apoptosis-Induced Ligand Gene in Relation to Tumor Necrosis Factor on Human Colon Cancer Cell Line HT29].

Tumor-targeted delivery of biologically active TRAIL protein

Effective Inhibition Of Cancer Cells By Recombinant Adenovirus Expressing Egfr-Targeting Artificial Microrna And Reversed-Caspase-3

Tumor Suppression Activity of Ginsenoside Rg3 Combined with TRAIL Gene on Human Colon Cancer Cell Line HCE8693

Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoter

Suppressing Orthotopic Pancreatic Tumor Growth With A Fiber-Modified Adenovector Expressing The Trail Gene From The Human Telomerase Reverse Transcriptase Promoter

Serotonergic receptor antagonists alter responses to general anaesthetics in rats.

Eukaryotic Expression and in Vitro Tumor Cell Apoptosis-induced Effect of Human TRAIL

Synergistic antitumoral effects of human telomerase reverse transcriptase-mediated dual-apoptosis-related gene vector delivered by orally attenuated Salmonella enterica Serovar Typhimurium in murine tumor models.

Radiotherapy Sensitization by Tumor-Specific TRAIL Gene Targeting Improves Survival of Mice Bearing Human Non–Small Cell Lung Cancer

Salmonella-mediated tumor-targeting TRAIL gene therapy significantly suppresses melanoma growth in mouse model.